Market Overview
At 01:08 AM Central Europe on Saturday 24 November 2026, Chugai Pharmaceutical (ticker 4519.T) closed 1.58 % higher than the previous trading day. The share price now trades at JPY 6,795, reflecting a modest uptick amid a broader trend of volatility in the Japanese equity market.
Trading Volume and Capitalisation
- Shares outstanding: 1.6 billion
- Market capitalisation: JPY 10.7 trillion
- 24‑hour volume: JPY 17.6 billion
These figures illustrate the depth of liquidity that surrounds Chugai, with a sizeable volume of shares exchanged within a short period. The company’s current price sits roughly 14 % below its 200‑day simple moving average of JPY 7,836.26, suggesting that the stock remains under pressure from longer‑term trend analysts.
Historical Context
- 52‑week high: JPY 10,700 (25 February 2026)
- 52‑week low: JPY 5,974 (2 October 2026)
The recent upward move brings Chugai closer to its recent all‑time peak, although the stock remains well below that level. The 52‑week range underscores the volatility inherent in the pharmaceutical sector, where regulatory approvals and clinical trial outcomes can swiftly alter investor sentiment.
Peer Comparison
A snapshot of contemporaneous Japanese pharmaceutical and financial institutions provides context for Chugai’s performance:
| Company | Ticker | 24‑hour change | Current price | Market cap | P/E ratio |
|---|---|---|---|---|---|
| KDDI | 9433.T | –0.12 % | JPY 2,865.5 | JPY 11.1 trillion | 14.96 |
| Shin‑etsu Chemical | 4063.T | –1.33 % | JPY 5,826 | JPY 10.9 trillion | 22.63 |
| Japan Post Bank | 7182.T | –1.05 % | JPY 2,961.5 | JPY 10.9 trillion | 17.92 |
| Hoya | 7741.T | –0.47 % | JPY 26,100 | JPY 8.9 trillion | 33.48 |
| Takeda Pharmaceutical | 4502.T | +0.52 % | JPY 6,389 | JPY 10.1 trillion | – |
Chugai’s modest rise contrasts with the broader downward drift observed in most of its peers, except for Takeda Pharmaceutical, which experienced a small gain. This divergence may reflect market participants’ confidence in Chugai’s pipeline and recent earnings guidance, relative to the more modest performance of its peers.
Company Profile
Chugai Pharmaceutical Co., Ltd. is a long‑standing Japanese healthcare company listed on the Tokyo Stock Exchange. Established by an IPO on 1 March 1956, the firm has maintained a robust presence in the pharmaceutical industry, focusing on the development, manufacturing, and sale of drugs for cancer, infectious diseases, bone disorders, hematology, and circulatory system conditions. In addition to commercial products, Chugai collaborates with both private and public medical research institutions worldwide to advance drug discovery and clinical studies.
The company’s website, accessible at www.chugai-pharm.co.jp , offers detailed information about its product portfolio, research initiatives, and corporate governance practices.
This article synthesises recent market data and contextual industry information to provide an informed snapshot of Chugai Pharmaceutical’s standing within Japan’s equity landscape.
